CD274 and head and neck squamous cell carcinoma: A Phase Ib/II trial (NCT03260023) is currently evaluating the safety of a combination of TG4001 and Avelumab (BAVENCIO, Merck and Pfizer), an anti-PD-L1 agent, as well as the efficacy of this combination against avelumab alone, in patients with HPV-16+ R/M cancers, including HNSCC.